A Cost–Consequence Analysis of Preemptive <i>SLCO1B1</i> Testing for Statin Myopathy Risk Compared to Usual Care

There is a well-validated association between <i>SLCO1B1</i> (rs4149056) and statin-associated muscle symptoms (SAMS). Preemptive <i>SLCO1B1</i> pharmacogenetic (PGx) testing may diminish the incidence of SAMS by identifying individuals with increased genetic risk before stat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Charles A. Brunette, Olivia M. Dong, Jason L. Vassy, Morgan E. Danowski, Nicholas Alexander, Ashley A. Antwi, Kurt D. Christensen
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
R
Acceso en línea:https://doaj.org/article/bce280f5a3324b0bba6cd0a0da6a1f6f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!